Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
Antiviral Agents
/ pharmacology
Benzimidazoles
/ pharmacology
Carbamates
/ pharmacology
Carcinoma, Hepatocellular
/ pathology
Drug Combinations
Drug Resistance, Viral
/ genetics
HIV Infections
/ complications
Hepacivirus
/ genetics
Hepatitis C, Chronic
/ complications
Heterocyclic Compounds, 4 or More Rings
/ pharmacology
Humans
Liver Cirrhosis
/ pathology
Liver Neoplasms
/ pathology
Liver Transplantation
/ adverse effects
Male
Middle Aged
Phosphoproteins
/ genetics
Pyrrolidines
/ pharmacology
Quinoxalines
/ pharmacology
RNA, Viral
/ genetics
Recurrence
Sofosbuvir
/ pharmacology
Sulfonamides
/ pharmacology
Sustained Virologic Response
Treatment Failure
Viral Load
/ drug effects
Viral Nonstructural Proteins
/ genetics
HIV infections
direct-acting antivirals
hepatitis C
liver transplant
resistance-associated substitutions
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
05
05
2019
revised:
20
07
2019
accepted:
25
08
2019
pubmed:
6
9
2019
medline:
1
5
2020
entrez:
6
9
2019
Statut:
ppublish
Résumé
Direct-acting antivirals (DAAs) demonstrated high efficacy and safety even in the post-liver transplant (LT) setting and in HIV-infected patients, but data are very limited in the early post-LT period with the most recently available DAA. Two HIV/HCV-coinfected LT recipients (both grafts from HIV/HCV-negative donors) experienced early HCV recurrence with severe hepatitis and were treated with sofosbuvir/velpatasvir for 12 weeks. Unfortunately, both patients failed: one (genotype 4d) showed virological breakthrough at week 3 with resistance-associated substitutions (RASs) for both NS5A and NS5B, while the other (genotype 1a) experienced virological relapse without RAS. Both progressed to fibrosing cholestatic hepatitis and were successfully retreated with glecaprevir/pibrentasvir for 16 weeks achieving sustained virological response. The higher prevalence of RAS in experienced genotype 4 patients and the long time to viral suppression observed in subjects with fibrosing cholestatic hepatitis should be taken into account, considering longer treatment duration to increase the chances of achieving sustained virological response.
Substances chimiques
Antiviral Agents
0
Benzimidazoles
0
Carbamates
0
Drug Combinations
0
Heterocyclic Compounds, 4 or More Rings
0
Phosphoproteins
0
Pyrrolidines
0
Quinoxalines
0
RNA, Viral
0
Sulfonamides
0
Viral Nonstructural Proteins
0
glecaprevir and pibrentasvir
0
nonstructural phosphoprotein 5A, GB virus type C
0
sofosbuvir-velpatasvir drug combination
0
NS-5 protein, hepatitis C virus
EC 2.7.7.48
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13165Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transplant. 2012;18(6):716-726.
Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12(7):1866-1876.
Antonini TM, Coilly A, Rossignol E, et al. Sofosbuvir-based regimens in HIV/HCV coinfected patients after liver transplantation: results from the ANRS CO23 CUPILT study. Transplantation. 2018;102(1):119-127.
Manzardo C, Londoño MC, Castells L, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: a prospective nationwide cohort study. Am J Transplant. 2018;18:2513-2522.
Terrault NA, Berenguer M, Strasser SI, et al. International liver transplantation society consensus statement on hepatitis C management in liver transplant recipients. Transplantation. 2017;101(5):956-967.
Agarwal K, Castells L, Müllhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol. 2018;69:603-607.
Reau N, Kwo PY, Rhee S, et al. Glecaprevir/Pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology. 2018;68(4):1298-1307.
Poordad F, Pol S, Asatryan A, et al. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2018;67(4):1253-1260.
Guaraldi G, Rossotti R, Verucchi G, et al. Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection. Open Forum Infect Dis. 2017;4(2):ofx065.
Howe A, Cento V, Knight N, et al. A real world resistance profile of virologic failures collected from an international collaboration (SHARED). Hepatology. 2018;68(1):128A.
Nguyen T, Akhavan S, Caby F, et al. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. Int J Antimicrob Agents. 2019;53(1):80-83.
Newsum AM, Molenkamp R, van der Meer JT, et al. Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission. J Hepatol. 2018;69:968-970.
Levitsky J, Verna EC, O'Leary JG, et al. Perioperative Ledipasvir-Sofosbuvir for HCV in liver-transplant recipients. N Engl J Med. 2016;375(21):2106-2108.